{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:38:58Z","timestamp":1793392738481,"version":"4.5.0"},"reference-count":22,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T00:00:00Z","timestamp":1667347200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Neurourology and Urodynamics"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Neurogenic detrusor overactivity incontinence (NDOI) is often inadequately managed with oral therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To assess efficacy and safety of abobotulinumtoxinA (aboBoNT\u2010A; Dysport\u00ae; Ipsen Ltd.) according to etiology of NDOI.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>Two phase III, randomized, double\u2010blind studies (CONTENT1 [NCT02660138] conducted in Asia, Europe and North America; CONTENT2 [NCT02660359] conducted in the Americas, Asia, Europe and Oceania) both included patients with spinal cord injury (SCI) or multiple sclerosis (MS), with inadequately managed NDOI, regularly performing clean intermittent catheterization (CIC).<\/jats:p><\/jats:sec><jats:sec><jats:title>Intervention<\/jats:title><jats:p>Patients in CONTENT1 and CONTENT2 received aboBoNT\u2010A injections 600\u2009U (<jats:italic>n<\/jats:italic>\u2009=\u2009162)\/800\u2009U (<jats:italic>n<\/jats:italic>\u2009=\u2009161), or placebo (<jats:italic>n<\/jats:italic>\u2009=\u2009162) into the detrusor muscle.<\/jats:p><\/jats:sec><jats:sec><jats:title>Outcome Measurements and Statistical Analysis<\/jats:title><jats:p>Primary endpoint: mean change from baseline in number of NDOI episodes\/week at Week 6. Secondary endpoints: proportion of patients with no NDOI episodes; incontinence\u2010related quality of life (I\u2010QoL); urodynamic parameters; and time\u2010to\u2010retreatment. Safety was also assessed. Statistical analyses were conducted for pooled populations by etiology (aboBoNT\u2010A doses vs. placebo).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results and Limitations<\/jats:title><jats:p>Of 485 randomized patients, 341 (70%) and 144 (30%) had SCI and MS etiologies, respectively. A significant reduction was observed in mean NDOI episodes\/week at Week 6 with both aboBoNT\u2010A doses versus placebo in the SCI (all <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and MS (all <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01) groups, as well as significant improvements in I\u2010QoL and urodynamic parameters. Median time\u2010to\u2010retreatment was longer in patients with MS (48\u201362 weeks across doses) than those with SCI (39\u201344 weeks). Safety data were similar between etiologies. Urinary tract infection was the most frequent adverse event; similar numbers were reported across treatment groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>AboBoNT\u2010A was well tolerated and significantly improved continence and bladder function, and QoL, in patients with SCI or MS with NDOI performing regular CIC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patient Summary<\/jats:title><jats:p>AboBoNT\u2010A injections improved QoL, symptoms, and bladder function in patients with SCI or MS with bladder muscle overactivity that causes incontinence.<\/jats:p><\/jats:sec>","DOI":"10.1002\/nau.25062","type":"journal-article","created":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T12:37:21Z","timestamp":1667392641000},"page":"153-167","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["AbobotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity regardless of spinal cord injury or multiple sclerosis etiology: Pooled analysis of two phase III randomized studies (CONTENT1 and CONTENT2)"],"prefix":"10.1002","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4831-6499","authenticated-orcid":false,"given":"Pierre","family":"Denys","sequence":"first","affiliation":[{"name":"Department of Neuro\u2010Urology and Andrology, Raymond\u2010Poincar\u00e9 Hospital Assistance Publique\u2010H\u00f4pitaux de Paris Garches France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3758-2361","authenticated-orcid":false,"given":"Juan Carlos","family":"Casta\u00f1o Botero","sequence":"additional","affiliation":[{"name":"Functional Urology CES University Clinic Medell\u00edn Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo Luis","family":"Vita Nunes","sequence":"additional","affiliation":[{"name":"Specialized Center in Urology Oswaldo Cruz German Hospital S\u00e3o Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barton","family":"Wachs","sequence":"additional","affiliation":[{"name":"Chief Urology Section Atlantic Urology Medical Group Long Beach California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8486-4003","authenticated-orcid":false,"given":"Cristiano","family":"Mendes Gomes","sequence":"additional","affiliation":[{"name":"Division of Urology University of S\u00e3o Paulo S\u00e3o Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grigory","family":"Krivoborodov","sequence":"additional","affiliation":[{"name":"Department of Urology Pirogov Russian National Research Medical University Moscow Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le Mai","family":"Tu","sequence":"additional","affiliation":[{"name":"Urology Division, Department of Surgery, Faculty of Medicine Sherbrooke University Hospital Center Sherbrooke Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Del\u2010Popolo","sequence":"additional","affiliation":[{"name":"Department of Neurourology Careggi University Hospital Florence Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Thompson","sequence":"additional","affiliation":[{"name":"June Pharma Consulting London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Vilain","sequence":"additional","affiliation":[{"name":"R&amp;D, Clinical Development Operations Department, Biostatistics and Sataistical Programing Group Ipsen Innovation Les Ulis France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Volteau","sequence":"additional","affiliation":[{"name":"R&amp;D, Clinical Development Operations Department, Biostatistics and Sataistical Programing Group Ipsen Innovation Les Ulis France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kennelly","sequence":"additional","affiliation":[{"name":"Department of Urology Atrium Health, Carolinas Medical Center Charlotte North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Dysport CONTENT program group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,11,2]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.23397"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.22636"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rehab.2016.02.006"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.04.028"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.2147\/RRU.S29644"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.56.3.245"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2007.09.034"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2006.06091.x"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/00365590601068835"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2004.11.009"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2009.08466.x"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2010.06.035"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.3121\/cmr.2007.716"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1159\/000083259"},{"key":"e_1_2_11_16_1","unstructured":"BlokB Castro\u2010Diaz D Del PopoloG GroenJ HamidR KarsentyG KesslerTM PannekJ. EAU Guidelines.Edn. presented at the EAU Annual Congress Amsterdam.2020."},{"key":"e_1_2_11_17_1","unstructured":"Allergan Inc. Highlights of prescribing information: Botox\u00ae.2017."},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-013-0054-z"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.03.010"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(99)80384-7"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.01.125"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.07.002"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2393"}],"container-title":["Neurourology and Urodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/nau.25062","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/nau.25062","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/nau.25062","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T02:21:37Z","timestamp":1692584497000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/nau.25062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,2]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1002\/nau.25062"],"URL":"https:\/\/doi.org\/10.1002\/nau.25062","archive":["Portico"],"relation":{},"ISSN":["0733-2467","1520-6777"],"issn-type":[{"value":"0733-2467","type":"print"},{"value":"1520-6777","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,2]]},"assertion":[{"value":"2022-08-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}